Inflammatory Bowel Disease Katie Benner VTS 2. Crohns & UC Complex disorders & wide variation in clinical practice Chronic idiopathic inflammaotry intestinal.

Slides:



Advertisements
Similar presentations
Medical Management of Ulcerative Colitis
Advertisements

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.
Colitis in the Very Young
Management of Inflammatory bowel disease 8/12/10.
Inflammatory Bowel Disease
Dr Samantha Chambers FY2 IBD. Aims What is IBD Differences between UC and Crohn’s Presentation Extra-intestinal manifestations Investigations Management.
Azathioprine for IBD : Better the devil you know Jeremy D. Sanderson.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
Ulcerative Colitis.
Therapy of Inflammatory Bowel Diseases 2013 Gastroenterology Department Division of Medicine Eran Israeli MD.
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Inflammatory bowel disease/ Irritable bowel syndrome Dr. Syed Md. Basheeruddin Asdaq.
Introduction to CCFA Arkansas Chapter and Inflammatory Bowel Diseases.
Inflammatory Bowel Disease Kimberly Persley, MD Digestive Disease Associates of Dallas Presbyterian Hospital of Dallas.
Inflammatory Bowel Disease
DRUG TREATMENT OF INFLAMMATORY BOWEL DISEASE. Objectives Describe the mechanism of action, pharmacokinetics and adverse effects of drugs in IBD.
Crohn’s disease - A Review of Symptoms and Treatment
UC. Ulcerative Colitis ( UC ) Ulcerative colitis is an inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract It is.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
Inflammatory Bowel Diseases Dr. Nematollah Ahangar Assistant Prof. of Pharmacology.
Case A 25-year-old woman A 4-m history of abdominal pain in the left lower quadrant and bloody diarrhea.
Inflammatory Bowel Disease (IBD)
Better Health. No Hassles. Colon Cancer Cancer of the large intestine 112,000 people are diagnosed annually 41,000 new cases of rectal cancer annually.
Cause of disability. Changes in the joint inflammation, proliferation of the synovium, errosion of cartilage & bones.
Understanding Lower Bowel Disease
By: Leon Richardson Period 2
Case Presentation. Female Patient AB Aged 20 First seen by me in August 2009 Had been diagnosed with Crohn’s Disease in March 2009.
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
Dr. Angus Lee SET 1 General Surgery. Burrill Crohn, an American Gastroenterologist, with his 2 other colleagues first described “Terminal ileitis” in.
Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Prof. Hanan Hagar Pharmacology Department College of Medicine.
CROHN’S DISEASE Alison Cunliffe. What is Crohn’s Disease?  Chronic inflammatory disease of the intestines  Causes ulcerations, breaks in the lining,
Ulcerative colitis.
Definitions UC Inflammation confined to mucosa Inflammation confined to mucosa Starting in rectum Starting in rectum May involve entire colon May involve.
“Antibiotics and corticosteroids: Indications and approaches”
Dr. Gholam Reza Khatami Ulcerative colitis is a chronic gastrointestinal disease Given modern treatment, medical management is not curative.
Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Prof. Hanan Hagar Pharmacology Unit College of Medicine.
IBD Patient Update Case Vignettes 12 November 2011.
Inflammatory bowel disease/ Irritable bowel syndrome Dr. Syed Md. Basheeruddin Asdaq.
CROHN’S DISEASE By: Omekia Wilkes. What is Crohn’s Disease?  Crohn’s disease is a type of inflammatory bowel disease that affects the intestines.  The.
Clinical Vignette: Medical Grand Rounds Joshua L. Denson MD Internal Medicine PGY2 January 7, 2013 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.
Cronhns & Ulcerative Colitis
Chronic inflammatory Bowel Diseases By Prof. Abdulqader Alhaider 1432 H.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
ULCERATIVE COLITIS. Ulcerative colitis is an idiopathic chronic inflammatory disease of the colon that follows a course of relapse and remission. In a.
Natalizumab- Unmet Need in the Management of Crohn’s Disease Doug Wolf, M.D. Atlanta Gastroenterology Associates July 31, 2007.
Disease modified Anti-rheumatic drugs ( DMARD)
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Kim Eastman RN,MSN, CNS. INFLAMMATORY BOWEL DISEASE  OVERVIEW  IMMUNOLOGIC DISEASE THAT RESULTS IN INTESTINAL INFLAMMATION  ULCERATIVE COLITIS  CROHN’S.
Ulcerative Colitis Rachel Gavin.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University.
What do these people all have in common?
IRRITABLE BOWEL SYNDROME
ULCERATIVE COLITIS Dr.Mohammadzadeh.
Inflammatory bowel disease
J.Livie1, E.Goodall1, M.Wilson2,C.Payne2 Department of Surgery2
IBD vs IBS diagnosis and management
Experience of Ulcerative Colitis and Crohn’s Disease Patients Treatment with Fetal Stem Cell Suspensions.
Inflammatory Bowel Disease
Ulcerative colitis (UC)
Inflammatory bowel disease: aminosalicylates
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Methotrexate for Ulcerative Colitis: To Use or Not to Use?
Lecture 12 Gastrointestinal Disorders Inflammatory Bowel Disease
“Drugs used in IBD and biological and immune therapy of IBD ”
Ulcerative Colitis Definition
Crohn’s Disease Biologic Pathway
Presentation transcript:

Inflammatory Bowel Disease Katie Benner VTS 2

Crohns & UC Complex disorders & wide variation in clinical practice Chronic idiopathic inflammaotry intestinal conditions Patients may find symptoms embarassing May result in loss of education/ employment difficulties Growth failure, psych probs, sexual development probs

Often presents young Lifelong disease Disproportionately high impact on society Hospital serving 300,000 sees new cases per annum Small increase in mortality for both

Approach to care High level of training Central hospitals supporting DGHs Rapid access to clinic appts for new/ known pts Provide counselling and educational material Access to private toilet facilities Multi disciplinary team

Patient’s experience See pts as individuals not as the disease Views on “right” and “wrong” life approaches to be avoided Respect pts expertise Sympathy, compassion & interest

Diagnosis Symptoms often dismissed as “stress related” Rapid access to hospital ixs Rapid referral to gastroenterologist specialising in IBD

History Stool frequency/ consistency/ urgency/ rectal bleeding/ tenesmus/ abdo pain/ malaise/ fever/ weight loss Extraintestinal- joint/ eye/ cutaneous Travel/ smoking/ FH/ medication

Examination General wellbeing Pulse, BP and temp Signs anaemia Fluid depletion, weight loss Abdo pain/ distension/ palp. masses Perineal exam

Investigations FBC/ U&E/ LFT/ ESR/ CRP Micro testing for infectious diarrhoea Additional tests for abroad travellers Abdominal imaging r/o toxic megacolon (in hosp) Felxi sigi/ colonoscopy (disease extent/ severity) Histopathology

Drugs used Rapidly evolving field, likely to change drastically in next 10 years Usually started in secondary care, but useful to know what they do, how to monitor, what side effects to watch out for

Aminosalicylates E.g. Mesalazine/ “Pentasa” Oral tablets/ sachets/ suspension/ liquid/ foam enemas/ suppositories act on epithelial cells by a variety of mechanisms to moderate the release of lipid mediators, cytokines, and reactive oxygen species Better tolerability than sulfasalazine Higher doses to induce remission

Aminosalicylates cont… Mesalazine intolerance in 15% Diarrhoea/ headache/ nausea/ rash

Corticosteroids Oral/ IV/ topical/ suppositories/ foam enemas Potent anti-inflammatories for moderate to severe relapses of CD or UC Combination of oral & rectal better 40mg pred optimal for outpatient management Too rapid a reduction assd with relapse

Corticosteroids cont.. Decision to use must be weighed up against risks Should be weaned slowly e.g. at 5mg/ week 50% pts report no adverse effects Cosmetic e.g. moon face, sleep & psychiatric

Thiopurines E.g. “azathioprine” mechanism of immunomodulation is by inducing T cell apoptosis by modulating cell signalling Note potential hepatotoxicity Need LFT monitoring (organised thru pharmacy) Use in active disease and maintaining remission

Thiopurines cont… Role is steroid sparing Consider in pts needing 2 or more courses steroids in a year (This is also when they need secondary care input) thiopurine methyl transferase (TPMT) must be tested 1 st If TPMT deficient ^ risk myelotoxicity

Thiopurines cont… 20% intolerance Flu like symptoms 2-3 weeks after started & resolve once drug withdrawn Profound leucopenia in 3% Hepatoxicity and pancreatitis in <5% Can be continued in pregnancy if IBD felt to be refractory

Methotrexate Unlicensed in IBD Oral/ IM/ SC Mechanism unclear Useful in inducing remission 25mg/week (15mg/week in RA) Measure FBC and LFT before starting and monthly thereafter

Methotrexate cont… Nausea/ vomiting/ diarrhoea/ stomatitis Limited by co-rx folic acid Pneumonitis occurs in 2-3%

Ciclosporin Inhibitor of calcineurin, preventing clonal expansion of T-cell subsets Rapid onset of action Used in mx severe UC Can be used as IV salvage therapy in those heading for colectomy Measurement of blood pressure, full blood count, renal function, and CsA concentration at 0, 1, and 2 weeks, then monthly

Ciclosporin cont… Minor side effects in 31-51% Tremor/ paraesthesia/ malaise/ headache, abnormal LFTs/ gingival hyperplasia/ hirsutism Major s/es in up to 17% Renal impairment/ infections/ neurotoxicity May require pneumocystis cariinei jab

Infliximab Chimeric anti-TNF monoclonal antibody with potent anti-inflammatory effects Needs to be done in secondary care Need maintenance doses, intitially after 2 weeks, 8+ weekly thereafter Need pre- infliximab virology checks (with pt consent), CXR and EBV in men under 30 Further doses given on PIU in Barnsley

Infliximab cont… Use with immunomodulator as increase interval between doses Rarely infusion reactions Delayed reactions of joint pain/ myalgia/ fever Theoretical risk of lymphoproliferative disorders

Surgery Disease not responding to intensive medical therapy Manage between surgeon and gastroenterologist Pre-operative conselling and involvement of stoma nurse specialist Subtotal colectomy leaving long rectal stump

Surveillance for colonic carcinoma UC pts should get repeat colonscopy in years Extensive colitis (opting for surveillance) 3- yearly in teens, 2-yearly in 20s and yearly in 30s Pts with PSC have higher risk of cancer and should have annual colonscopies

Pt information NACC: The National Association for Colitis and Crohn’s disease, 4 Beaumont House, Sutton Road, St Albans, Herts AL1 5HH, UK. Information Line: ; website: CCFA: The Crohn’s and Colitis Foundation of America; website: CORE/DDF: Digestive Diseases Foundation, PO Box 251, Edgware, Middlesex, HA8 6HG, UK.

Who to contact? Debbie (IBD specialist nurse) on bleep 591 or Specific IBD advice line 2-3pm

References British Society of Gastroenterology Guidelines for the management of inflammatory bowel disease in adults Gut 2004

Thank you Any questions?